Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 6, 2017, Pages 858-865

  Harris, Stewart B ^a   Kocsis, Győző ^b   Prager, Rudolf ^c   Ridge, Terry ^d   Chandarana, Keval ^e   Halladin, Natalie ^e   Jabbour, Serge ^f  

^a WESTERN UNIVERSITY   (Canada)

^b Peterfy Hospital   (Hungary)

^c Hietzing Hospital   (Austria)

^d American Health Network   (United States)

^e NOVO NORDISK A S   (Denmark)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

efficacy; insulin therapy; randomized clinical trials; safety; type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL LIPASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIRAGLUTIDE; LONG ACTING INSULIN;

ADULT; ADVERSE DRUG REACTION; ALGORITHM; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMALE GENITAL TRACT CANCER; GLUCOSE BLOOD LEVEL; HEADACHE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SYMPTOM; TREATMENT DURATION; WEIGHT CHANGE; AGED; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; EQUIVALENCE TRIAL (TOPIC); MIDDLE AGED; TREATMENT OUTCOME;

AGED; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EQUIVALENCE TRIALS AS TOPIC; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 85019638028     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12892     Document Type: Article

References (28)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
3. Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. Br J Diabetes Vasc Dis. 2015;15:65-69.
4. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract. 2009;164:6-10.
5. Peyrot M, Rubin RR, Lauritzen T, et al, International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study. Diabetes Care. 2005;28:2673-2679.
6. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care. 2009;15:e22-e33.
7. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 2012;18:527-539.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.
9. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007;113:546-593.
10. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in patients with type 2 diabetes (LEAD-1 SU). Diabet. Med. 2009;26:268-278.
11. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
12. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;20:2228-2234.
13. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885-893.
14. Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;17:965-973.
15. Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37:2926-2933.
16. Greig SL, Scott LJ. Insulin degludec/liraglutide: a review in type 2 diabetes. Drugs. 2015;75:1523-1534.
17. Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315:898-907.
18. Rosenstock JGrunberger G, et al., Aronson R, Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O Randomized Trial. Diabetes Care. 2016;39:2026–2035.
19. Davies M, Storms F, Shutler S, Blanchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvement of glycemic control in patients with poorly controlled type 2 diabetes. Diabetes Care. 2005;28:1282-1288.
20. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet. Med. 2006;23:736-742.
21. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Last amended by the 64th WMA Assembly; October 2013; Fortaleza, Brazil.
22. International Conference on Harmonisation. ICH harmonised tripartite guideline. Good Clinical Practice. 10 June 1996.
23. FDA Guidance. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071624.pdf. Accessed April 4, 2016.
24. Keating GM. Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. Drugs. 2013;73:575-593.
25. Perry CM. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2011;71:2347-2373.
26. Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naïve patients with type 2 diabetes mellitus. J. Diabetes. 2014;6:176-183.
27. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36:S127-S138.
28. Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(suppl):S139-S144.